Analyst consensus rating
Protara Therapeutics Analyst Rating: Strong Buy
Direct answer
Protara Therapeutics's consensus rating is Strong Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $25.33.
Forecast evidence checked November 21, 2026.
Get free Protara Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.28
- Average price target
- $25.33
- High price target
- $30.00
- Low price target
- $18.00
- Low target gap
- +689.5%
- Target upside
- +1,011.1%
- High target gap
- +1,215.8%
- Target range width
- 526.3%
- Consensus rating
- Strong Buy
- Analysts
- 6
- Evidence date
- November 21, 2026
- Valid through
- November 28, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Protara Therapeutics?
Protara Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $25.33.
How far are Protara Therapeutics's low and high targets from the recorded price?
The low target implies +689.5%, while the high target implies +1,215.8%.
How many analysts are included in Protara Therapeutics's consensus?
The verified consensus includes 6 analysts.
How is Protara Therapeutics's target upside or downside calculated?
The average target of $25.33 is divided by the recorded price of $2.28, then one is subtracted to produce +1,011.1%. This does not guarantee a future return.
When was Protara Therapeutics's analyst forecast verified?
The data was verified on 2026-11-21. The dataset is valid through 2026-11-28.